Iproniazid (phosphate)

Iproniazid phosphate is an orally active, irreversible, non-selective monoamine oxidase (MAO) inhibitor. Iproniazid phosphate inhibits MAO activity and enhances Rotenone (HY-B1756)-induced Apoptosis. Iproniazid phosphate modulates neurotransmitter levels, affects neuronal function, induces hepatic necrosis, and interferes with the endocrine system. Iproniazid phosphate can be used in the research of depression, Parkinson's disease, and hepatotoxicity^{[1][2][3][4][5][6][7]}. In Vitro:Iproniazid (10 mM; 24 h) phosphate increases intracellular dopamine content and accelerates DNA fragmentation induced by 0.1 μM Rotenone (HY-B1756) in SH-SY5Y cells^[2].
Iproniazid (100 μM; 10 min) phosphate inhibits serotonin metabolism by monoamine oxidase in cultured guinea pig tracheal smooth muscle cells^[3].
In Vivo:Iproniazid (100 mg/kg; i.p.; 150 min before Lidocaine administration) phosphate lowers the median convulsant dose of Lidocaine in mice, reducing the seizure threshold ^[4].
Iproniazid (i.p.) phosphate causes hepatic necrosis in Sprague-Dawley and Fischer rats^[5].
Iproniazid dihydrochloride (53-224 mg/kg; p.o.; daily) phosphate retards sexual maturation, lengthens the estrous cycle, and inhibits corpus luteum formation in female rats^[6].